Picture of BRAIN Biotech AG logo

BNN BRAIN Biotech AG Cashflow Statement

0.000.00%
de flag iconLast trade - 00:00
IndustrialsAdventurousSmall CapNeutral

Annual cashflow statement for BRAIN Biotech AG, fiscal year end - September 30th, EUR millions except per share, conversion factor applied.

2019
September 30th
2020
September 30th
2021
September 30th
2022
September 30th
2023
September 30th
Period Length:12 M12 M12 M12 M12 M
Source:ARSARSARSARSARS
Standards:
IFRS
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-10.5-9.02-4.68-6.34-8.11
Depreciation
Deferred Taxes
Non-Cash Items-0.153-0.998-4.82-3.07-1.35
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital2.881.291.343.640.139
Change in Accounts Receivable
Change in Inventories
Change in Other Assets
Change in Accounts Payable
Change in Other Liabilities
Net Change in Other Assets & Liabilities
Other Operating Cash Flow
Cash from Operating Activities-3.38-4.77-3.91-1.49-4.22
Capital Expenditures-6.64-2.86-1.26-6.08-2.64
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items-0.106-1.61-0.918-6.63.2
Acquisition of Business
Sale of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities-6.74-4.47-2.18-12.70.562
Financing Cash Flow Items0.00614.614.40-9.59
Other Financing Cash Flow
Net Issuance / Retirement of Debt
Cash from Financing Activities-0.27613.111.6-1.970.459
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash-10.43.785.6-16.1-3.09